Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

Inmagene

Status and phase: Invitation-only; Phase 2

Conditions: Atopic Dermatitis; Atopic Dermatitis Eczema; Eczema

Treatments: Drug: IMG-007

Study type: Interventional

Funder types: Industry

Identifiers

NCT07734415

IMG-007-205

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)

Enrollment: 400 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Enrolling by invitation participants with moderate to severe AD who have completed IMG-007-203

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

400 participants in 1 patient group

IMG-007 Dose

Experimental group

Description:

Subcutaneous injection as per protocol.

Treatment:

Drug: IMG-007